Ispectamab debotansine

DB18456InvestigationalProtein Based Therapies

Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 17
Curator reviewed
Code names: BMS-986352 · CC-99712

Resolves to

Compound

UNIIWY39ZX6NZUCAS2413386-21-5

Targets

Q02223TNFRSF17

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Ispectamab debotansine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account